HIVandHepatitis.com
HIV and AIDS Topics
Top News Articles
 
FDA-approved Treatments 
Experimental Treatments
Women / Children
Metabolic Complications
Opportunistic Infections
 Google Custom Search
World Health Organization Says the BCG Tuberculosis Vaccine Is Too Dangerous for HIV Positive Infants

The World Health Organization (WHO) now recommends that use of the Bacille Calmette-Guérin (BCG) vaccine against tuberculosis (TB) be delayed until infants can be tested for HIV. A new WHO study finds BCG, which is routinely given to 75 percent of babies worldwide, is too risky for those born infected with HIV.

In use since 1921, the BCG vaccine is effective against deadly TB meningitis, though it is less so against the TB lung disease. Because it is a live vaccine, it can cause "disseminated BCG disease," a type of whole-body bacterial infection that is fatal in more than 70 percent of cases.

In countries with co-existing TB and HIV epidemics, giving BCG to HIV-infected newborns offers them no protection against TB and may kill them due to BCG disease, according to the WHO study, which was performed at three South African pediatric hospitals.

Since BCG disease and TB can look identical, the researchers had to culture each infection individually. Although the researchers recommended delaying BCG vaccination, they said this will not be easy. In poor countries, babies are frequently not brought back at six weeks for a test and 10 weeks for a shot. Thus the practice of vaccinating every newborn may continue, since it protects the ones not infected with HIV.

In conclusion, the study authors wrote, "Multicentre surveillance data showed that the risk of disseminated BCG disease in HIV-infected infants is considerably higher than previously estimated, although likely to be under-estimated."

The also stated, "There is an urgent need for data on the risk-benefit ratio of BCG vaccination in HIV-infected infants to inform decision-making in settings where HIV infection and tuberculosis burdens are high. Safe and effective tuberculosis prevention strategies are needed for HIV-infected infants."

Source
DG. McNeil Jr. Tuberculosis: TB Vaccine Too Dangerous for Babies with AIDS Virus, Study Says. New York Times. July 2, 2009.

Reference
AC Hesseling, LF Johnson, H Jaspan, and others. Disseminated Bacille Calmette-Guérin Disease in HIV-Infected South African Infants [Full article] Bulletin of the World Health Organization 87(7): 485-564. 2009.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Protease Inhibitors
Agenerase (amprenavir)
Aptivus
(tipranavir)
Crixivan
(indinavir)
Invirase
(saquinavir hard gel)
Kaletra
(lopinavir/ritonavir)
Lexiva
(fosamprenavir)
Norvir
(ritonavir)
Prezista
(darunavir)
Reyataz
(atazanavir)
Viracept
(nelfinavir)
Nucleoside / Nucleotide Reverse
Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry
(maraviroc)
Fixed Dose Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)